Anti-Human IGF-I/IGF-1 Reference Antibody (Xentuzumab, RUO)

Description: Research Grade Xentuzumab (BS10043) is a humanized monoclonal antibody detecting IGF-I in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights:
• Multi-Application — Validated across multiple applications.
Host species: Humanized
Isotype: IgG1-lambda
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: IGF-I,IGF1,Mechanogrowthfactor,MGF,Insulin-likegrowthfactorI,IBP1,Somatomedin-C,IGF2,IGF-II,Insulin-likegrowthfactorII,T3M-11-derivedgrowthfactor,Somatomedin-A
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BI836845,CAS:1417158-65-6
Background: Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.
Note: For research use only. Not suitable for clinical or therapeutic use.